https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-01 / Oncoimmunology 2017;6(9):e1207032
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-01 / Oncoimmunology 2017;6(9):e12070322016-07-01 00:00:002016-07-01 00:00:00Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER/HER2 early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-502
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-5022016-07-01 00:00:002019-02-15 08:47:28Immunological Aspects of Malignant Gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-29 / J. Immunol. 2016 08;197(3):795-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-29 / J. Immunol. 2016 08;197(3):795-8062016-06-29 00:00:002019-02-15 08:48:41NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-145
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-1452016-06-27 00:00:002016-06-27 00:00:00HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-2528
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-25282016-06-20 00:00:002019-02-15 08:49:43Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)2016-06-17 12:11:492019-07-17 12:12:15Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e1201625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e12016252016-06-17 00:00:002016-06-17 00:00:00Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-232016-06-09 00:00:002019-02-15 08:32:44Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr e12566)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr e12566)2016-06-05 12:12:422019-07-17 12:13:35Dendritic cells-based vaccine to inhibit triple-negative breast cancer cells proliferation.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1086)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1086)2016-06-05 12:10:572019-07-17 12:11:24Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
